XNYS
ARE
Market cap9.82bUSD
Sep 17, Last price
56.34USD
1D
5.27%
1Q
10.41%
Jan 2017
-49.30%
Name
Alexandria Real Estate Equities Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® real estate investment trust, stands as the pioneering and most seasoned entity in the specialized domain of urban office properties. Since its inception in 1994, Alexandria has uniquely focused on the ownership, operation, and development of integrated campuses tailored for the life science, technology, and agtech sectors, strategically positioned within premier innovation ecosystems. By December 31, 2020, the company commanded a market capitalization of $31.9 billion and managed an extensive North American asset portfolio totaling 49.7 million square feet. This substantial base encompasses 31.9 million RSF of operational properties, 3.3 million RSF of premium Class A spaces currently under construction, 7.1 million RSF designated for near-to-mid-term development and refurbishment, and an additional 7.4 million SF earmarked for future projects. Alexandria has cultivated a significant footprint across vital innovation hubs such as Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Its established expertise lies in crafting superior Class A facilities within these urban campuses, fostering dynamic and collaborative environments. These spaces are instrumental in empowering innovative tenants to successfully attract and retain world-class professionals, thereby stimulating productivity, efficiency, creativity, and overall achievement. Furthermore, Alexandria extends its support to transformative life science, technology, and agtech companies through its dedicated venture capital platform. This distinct business model, coupled with rigorous underwriting practices, ensures a diverse and high-caliber tenant roster, ultimately driving elevated occupancy rates, extended lease durations, robust rental revenues, superior financial returns, and enhanced long-term asset appreciation.
Related entities
Subsidiaries (3)
Alexandria Venture Investments, LLC
Alexandria Equities No. 7, LLC
ARE-MA Region No. 45, LLC
Key people
Thomas J. Andrews
Co-President, Regional Market Director � Greater Boston · since 2018
Dean Akio Shigenaga
Co-President, Chief Financial Officer · since 2018
Peter M. Moglia
Co-Chief Executive Officer and Co-Chief Investment Officer · since 2018
Stephen A. Richardson
Co-Chief Executive Officer · since 2018
Jennifer J. Banks
Co-Chief Operating Officer, General Counsel, Corporate Secretary · since 2018
Lawrence J. Diamond
Co-Chief Operating Officer, Regional Market Director � Maryland · since 2018
Marc E. Binda
Executive Vice President - Finance, Treasurer · since 2019
John H. Cunningham
Executive Vice President, Regional Market Director - New York City · since 2017
Andres R. Gavinet
Chief Accounting Officer · since 2012
Daniel J. Ryan
Co-Chief Investment Officer and Regional Market Director � San Diego · since 2018
Joseph Hawkman
Chief Strategic Transactions Officer · since 2019
Executive Chairman of the Board · since 2018
James H. Richardson
Director · since 2009
John L. Atkins
Independent Director · since 2007
James P. Cain
Independent Director · since 2015
Lead Independent Director · since 2016
Richard Hunter Klein
Independent Director · since 2003
Michael A. Woronoff
Independent Director · since 2017
Legal address
C/O CSC-LAWYERS INCORPORATING SERVICE COMPANY
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
Headquarters
7 ST. PAUL STREET
SUITE 820
BALTIMORE, MD 21202
US
SUITE 820
BALTIMORE, MD 21202
US
Previous name
Health Science Properties, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||